Tianjin Lisheng Pharmaceutical (002393.SZ): Potassium chloride sustained-release tablets approved through listing permit application

26/08/2025

Lifetech Pharmaceuticals (002393.SZ) announced that the company has received a notification from the National Medical Products Administration regarding the extended-release potassium chloride...

Tianjin Lisheng Pharmaceutical (002393.SZ) announced that the company has received the "Drug Registration Certificate" for the 0.5g specification of potassium chloride sustained-release tablets and the "Drug Registration Certificate" for the 0.6g specification of potassium chloride sustained-release tablets issued by the National Medical Products Administration. The above-mentioned drugs have passed the drug market approval application. The indications for potassium chloride sustained-release tablets are: used for the treatment and prevention of hypokalemia with or without metabolic alkalosis. In these patients, dietary management with potassium-rich foods or a reduction in diuretic dose is ineffective.

BOCOM INTL (03329) releases interim results, with shareholders' net loss of HK$283 million, a year-on-year decrease of 20.47%.

Firmly focusing on the core business direction, LINKLOGIS-W (09959) achieved a main operating income and profit of 375 million yuan in the first half of the year.

ADTIGER CORP(01163) releases its interim financial results, with a profit of 1.787 million yuan for the period, turning a loss into a profit compared to the same period last year.

BOCOM INTL (03329) releases interim results, with shareholders' net loss of HK$283 million, a year-on-year decrease of 20.47%.

Firmly focusing on the core business direction, LINKLOGIS-W (09959) achieved a main operating income and profit of 375 million yuan in the first half of the year.

ADTIGER CORP(01163) releases its interim financial results, with a profit of 1.787 million yuan for the period, turning a loss into a profit compared to the same period last year.